Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Short Interest Down 5.5% in June

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) saw a large decrease in short interest in June. As of June 15th, there was short interest totalling 1,710,000 shares, a decrease of 5.5% from the May 31st total of 1,810,000 shares. Based on an average daily trading volume, of 302,500 shares, the days-to-cover ratio is currently 5.7 days.

Actinium Pharmaceuticals Trading Up 4.6 %

ATNM opened at $7.28 on Thursday. The firm has a market capitalization of $216.80 million, a price-to-earnings ratio of -4.26 and a beta of 0.20. Actinium Pharmaceuticals has a twelve month low of $4.00 and a twelve month high of $10.24.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.11. Research analysts predict that Actinium Pharmaceuticals will post -1.57 earnings per share for the current year.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Creative Financial Designs Inc. ADV lifted its position in shares of Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Sanders Morris Harris LLC acquired a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth about $78,000. Vanguard Group Inc. grew its holdings in shares of Actinium Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares in the last quarter. Finally, Virtu Financial LLC increased its position in shares of Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company’s stock valued at $642,000 after acquiring an additional 62,459 shares during the last quarter. Institutional investors and hedge funds own 27.50% of the company’s stock.

Analysts Set New Price Targets

ATNM has been the subject of a number of analyst reports. Stephens began coverage on Actinium Pharmaceuticals in a report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, June 17th. Maxim Group lifted their target price on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th. Finally, StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, May 5th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Actinium Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $25.60.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.